Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16302724 | 0.92 | LMNA (0.35) | TSHRLMNAPKMKMT2A | |
| SCHEMBL1302057 | 0.91 | METTL3 (0.33) | TSHRHSD17B10 | |
| SCHEMBL1300512 | 0.91 | METTL3 (0.33) | TSHRHSD17B10 | |
| SCHEMBL3652800 | 0.90 | TSHR (0.31) | TSHRHSD17B10MEN1ABCC4LMNA | |
| SCHEMBL1301119 | 0.88 | METTL3 (0.31) | MEN1ABCC4LMNAPKMPTGS1 | |
| SCHEMBL1301120 | 0.88 | METTL3 (0.31) | MEN1ABCC4LMNAPKMPTGS1 | |
| SCHEMBL3656178 | 0.85 | LMNA (0.35) | TSHRLMNAKMT2A | |
| SCHEMBL1301673 | 0.85 | LMNA (0.35) | TSHRLMNAKMT2A | |
| SCHEMBL1300518 | 0.83 | METTL3 (0.36) | TSHRHSD17B10 | |
| SCHEMBL1301866 | 0.83 | METTL3 (0.34) | TSHRHSD17B10MEN1ABCC4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231665-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009089263-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | TSHR 4868/4885HSD17B10 617/4885MEN1 4555/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | TSHR 4868/4885HSD17B10 617/4885MEN1 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.